Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX) have received an average rating of “Buy” from the six brokerages that are presently covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $30.00.

Several brokerages recently issued reports on AVTX. Piper Sandler started coverage on shares of Avalo Therapeutics in a research report on Friday, February 28th. They issued an “overweight” rating and a $48.00 target price for the company. Stifel Nicolaus initiated coverage on Avalo Therapeutics in a research report on Tuesday, March 25th. They set a “buy” rating and a $36.00 price objective on the stock. Jefferies Financial Group assumed coverage on Avalo Therapeutics in a report on Tuesday, March 25th. They set a “buy” rating and a $23.00 price objective on the stock. HC Wainwright upgraded shares of Avalo Therapeutics from a “hold” rating to a “buy” rating and set a $15.00 price target on the stock in a research report on Monday, June 2nd. Finally, Wedbush restated an “outperform” rating and issued a $18.00 price objective on shares of Avalo Therapeutics in a report on Thursday, March 20th.

Avalo Therapeutics Stock Down 5.3%

AVTX stock opened at $4.10 on Friday. Avalo Therapeutics has a twelve month low of $3.39 and a twelve month high of $16.00. The stock has a 50-day simple moving average of $4.60 and a two-hundred day simple moving average of $6.89.

Avalo Therapeutics (NASDAQ:AVTX) last announced its earnings results on Monday, May 12th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.07) by ($0.18). As a group, equities analysts predict that Avalo Therapeutics will post -19.07 EPS for the current fiscal year.

Institutional Trading of Avalo Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of AVTX. Tower Research Capital LLC TRC grew its holdings in shares of Avalo Therapeutics by 998.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company’s stock worth $31,000 after purchasing an additional 3,754 shares during the last quarter. ADAR1 Capital Management LLC purchased a new stake in Avalo Therapeutics during the 1st quarter valued at $80,000. Marshall Wace LLP bought a new stake in Avalo Therapeutics in the 4th quarter worth $114,000. Walleye Capital LLC purchased a new position in shares of Avalo Therapeutics in the fourth quarter valued at about $145,000. Finally, Northern Trust Corp purchased a new position in shares of Avalo Therapeutics in the fourth quarter valued at about $168,000. Institutional investors own 87.06% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.